Peripheral T Cell Lymphoma: Understanding and Treatment
Author Information
Author(s): Agostinelli C, Piccaluga P P, Went P, Rossi M, Gazzola A, Righi S, Sista T, Campidelli C, Zinzani P L, Falini B, Pileri S A
Primary Institution: Department of Haematology and Clinical Oncology “L and A Seràgnoli”, Bologna University School of Medicine, Bologna, Italy
Hypothesis
What are the pathobiological characteristics and potential therapeutic targets for Peripheral T Cell Lymphoma, not otherwise specified (PTCL/NOS)?
Conclusion
PTCL/NOS is characterized by aggressive behavior and poor response to conventional therapies, but novel microarray technologies may help identify new treatment strategies.
Supporting Evidence
- PTCL/NOS accounts for about 12% of lymphoid tumors worldwide.
- Conventional therapies have poor outcomes, with 5-year survival rates around 20%.
- Gene expression profiling has identified 155 genes that may be targeted for new therapies.
- High Ki-67 expression (>80%) is associated with worse prognosis.
- PTCL/NOS often shows aberrant expression of T cell associated antigens.
Takeaway
Peripheral T cell lymphomas are a type of cancer that can be hard to classify and treat, but researchers are finding new ways to understand and target them.
Methodology
The study involved gene expression profiling and immunohistochemistry on tissue samples from patients with PTCL/NOS.
Limitations
The molecular pathobiology of PTCL/NOS is poorly understood, and previous studies have had limitations in methodology and sample selection.
Participant Demographics
Patients were primarily from Italy, with a mean age in the fifth to sixth decade of life and no significant sex predilection.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website